A phase I study of docetaxel and flavopiridol, a pan-cyclin-dependent kinase inhibitor, demonstrated encouraging clinical activity in PC.
Early single centre prospective development studies using high intensity focused ultrasound (HIFU) have demonstrated encouraging genitourinary functional preservation and short-term cancer control.
One-year safety and effectiveness results of the Nellix pivotal trial demonstrated encouraging outcomes with very low morbidity and mortality and high procedural and treatment success.
Many of these compounds exhibited nanomolar antiproliferation activities against human tumor lines in in vitro cell culture experiments, and a representative example (compound 26) demonstrated encouraging in vivo efficacy in a mouse xenograft tumor model derived from the A2780 cell line.
This study established some of the pitfalls when implementing a community-based transitional care program and demonstrated encouraging outcomes.
Phase I clinical trials of curcumin demonstrated encouraging chemopreventive effects in patients with high-risk or pre-malignant lesions.
PI3K inhibitors have demonstrated encouraging preliminary activity in the treatment of metastatic breast cancer, with responses observed in patients with and without PIK3CA and PTEN alterations.
Recently, combination therapy based on chemotherapeutic drugs or molecular-targeted agents have demonstrated encouraging synergistic antitumor effects and relieved the intolerable side-effects usually caused by chemotherapy drugs.
Finally, BGC9331 has demonstrated encouraging phase I and II activity in relapsed ovarian cancer (Plummer et al, 2003; Rader et al, 2003).
Ongoing research has led to the development of a third generation of MDR modulators, some of which have demonstrated encouraging results compared with earlier generation MDR modulators.
During early-phase clinical evaluation, the combination of cediranib with mFOLFOX6 demonstrated encouraging antitumour efficacy in patients with mCRC (Chen et al, 2009).
